A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.

NCT01803711 Phase 2/Phase 3 TERMINATED Results posted

To assess the efficacy of Omega 3 Fatty acid (Omega 3 FA) augmentation of desvenlafaxine (DVS) compared to placebo augmentation of DVS when used to treat depression and anxiety symptoms in patients with select medical conditions (cancer, cardiovascular diseases and diabetes).

Details

Lead sponsor	UConn Health
Phase	Phase 2/Phase 3
Status	TERMINATED
Enrolment	6
Start date	2013-02
Completion	2016-06

Conditions

• Major Depression
• Cancer
• Diabetes
• Cardiovascular Diseases

Interventions

• Desvenlafaxine
• Omega 3 Fatty acids
• Placebo (for Omega 3 fatty acid supplement)

Primary outcomes

• Hospital Anxiety and Depression Scale — 12 weeks from baseline
  Hospital Anxiety and Depression Scale: This is a validated scale for measuring depression/anxiety symptoms in patients with medical conditions.

Countries

United States